HealthLinx Releases Initial Results from First Stage of 1,150-Subject OvPlex Study

According to an initial analysis of the first-stage data, OvPlex was able to distinguish between stage I and II epithelial ovarian cancer patients and controls with 92 percent accuracy, compared to 80 percent accuracy for the conventional CA125 test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.